Alzheimer's drug hunt learns from cancer fight's multi-target playbook

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
Nasdaq

3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs

Eli Lilly has been investing in radiopharmaceuticals, which can help revolutionize cancer care in the future. Its early Alzheimer's drug, Kisunla, has blockbuster potential, and if efforts at early ...
Morning Overview on MSN

A new drug may stop Alzheimer’s before memory loss starts

Alzheimer’s disease has long been a diagnosis that arrives only after memory begins to fray, by which time brain damage is ...
PMLive

Lilly and Indiana University collaborate to expand clinical trial access

Eli Lilly and Indiana University (IU) have announced a new agreement, under which Lilly will provide up to $40m to IU in ...